Nxera exercises its option for exclusive rights to Idorsia's lucerastat for Fabry disease in Japan and Asia ex-China. Read ...
Oruka's ORKA-001 hit 61% complete skin clearance in Phase IIb EVERLAST-B psoriasis trial. Phase III. Read the full results ...
Teva acquires worldwide rights to BXCL501 sublingual film from BioXcel: $57.5M upfront, up to $125M total. Read the full deal ...
Insilico's AI-designed pan-TEAD inhibitor ISM6331 posted a 40% objective response rate at 130 mg in early mesothelioma data.
Rhode Island and Massachusetts life science groups sign MOU to plan a shared regional biobank for brain disease research.
GSK's Ris-Rez cut progression or death risk 67% vs chemotherapy in relapsed osteosarcoma. Read the Phase III results and what ...
Corxel Pharmaceuticals will list on Nasdaq via Amanat Acquisition Corp in a deal targeting $377M. Read how this ...
Rumi Therapeutics signs an option to license RTX-7340 from Enthorin for Fragile X syndrome. Read the full story on this ...
Merck's sac-TMT met both primary endpoints in Phase III TroFuse-005 for advanced endometrial cancer and is heading to FDA ...
Incyte's INCB161734 KRAS G12D inhibitor posted 89% and 81% objective response rates in Phase I PDAC and CRC data at ESMO 2026 ...
Kelun-Biotech's final OS analysis of Phase III OptiTROP-Lung04 shows sac-TMT extended median overall survival in lung cancer.
Genentech's divarasib beat sotorasib and adagrasib on PFS and OS in a Phase III NSCLC trial. Read the full results and what they mean for KRAS G12C treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results